File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice

TitleBiodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice
Authors
FAN, NZhao, JZhao, WSHEN, YSONG, QShum, HCWang, YRong, J
Issue Date2022
Citation
Biomaterials Science, 2022, v. 10, p. 984-996 How to Cite?
DOI: http://dx.doi.org/10.1039/D1BM01637G
Persistent Identifierhttp://hdl.handle.net/10722/313797
ISSN
2047-4830
2021 Impact Factor: 7.590
2020 SCImago Journal Rankings: 1.422
ISI Accession Number ID
WOS:000741639800001
AwardObesity is hallmarked by endoplasmic reticulum (ER) stress, chronic inflammation and metabolic dysfunctions. The control of obesity is the key to preventing the onset of non-alcoholic fatty liver disease, diabetes, cerebro-cardiovascular diseases and cancers. As a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications. The present study was designed to develop a biocompatible albumin-based nanoparticle carrier system for the controlled release of celastrol in diet-induced obese mice. Celastrol was loaded into bovine serum albumin (BSA) nanoparticles to yield celastrol-BSA-NPs by high pressure homogenization. Celastrol-BSA-NPs exhibited spherical morphology, narrow size distribution with a diameter of 125.6 ± 2.2 nm, satisfactory drug-loading efficiency at 13.88 ± 0.12% and a sustained-release profile over a period of 168 h. Compared with free celastrol, celastrol-BSA-NPs effectively improved cellular uptake, intestinal absorption and hepatic deposition. In animal experiments, celastrol-BSA-NPs outperformed free celastrol in lowering lipid accumulation, improving insulin sensitivity, and reducing inflammation in diet-induced obesity. Collectively, celastrol-BSA-NPs exhibited better bioavailability and in vivo efficacy in the treatment of diet-induced obesity. Importantly, such albumin-based nanoparticles may be a general biocompatible drug carrier system for the controlled release of hydrophobic compounds (e.g., celastrol) for the treatment of obesity and non-alcoholic fatty liver disease.

 

DC FieldValueLanguage
dc.contributor.authorFAN, N-
dc.contributor.authorZhao, J-
dc.contributor.authorZhao, W-
dc.contributor.authorSHEN, Y-
dc.contributor.authorSONG, Q-
dc.contributor.authorShum, HC-
dc.contributor.authorWang, Y-
dc.contributor.authorRong, J-
dc.date.accessioned2022-07-05T05:05:53Z-
dc.date.available2022-07-05T05:05:53Z-
dc.date.issued2022-
dc.identifier.citationBiomaterials Science, 2022, v. 10, p. 984-996-
dc.identifier.issn2047-4830-
dc.identifier.urihttp://hdl.handle.net/10722/313797-
dc.languageeng-
dc.relation.ispartofBiomaterials Science-
dc.titleBiodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice-
dc.typeArticle-
dc.identifier.emailZhao, J: zhaojia7@hku.hk-
dc.identifier.emailShum, HC: ashum@hku.hk-
dc.identifier.emailWang, Y: yuwanghk@hku.hk-
dc.identifier.emailRong, J: jrong@hku.hk-
dc.identifier.authorityShum, HC=rp01439-
dc.identifier.authorityWang, Y=rp00239-
dc.identifier.authorityRong, J=rp00515-
dc.identifier.doi10.1039/D1BM01637G-
dc.identifier.pmid35019905-
dc.identifier.scopuseid_2-s2.0-85124636402-
dc.identifier.hkuros333969-
dc.identifier.volume10-
dc.identifier.spage984-
dc.identifier.epage996-
dc.identifier.isiWOS:000741639800001-
dc.description.awardObesity is hallmarked by endoplasmic reticulum (ER) stress, chronic inflammation and metabolic dysfunctions. The control of obesity is the key to preventing the onset of non-alcoholic fatty liver disease, diabetes, cerebro-cardiovascular diseases and cancers. As a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications. The present study was designed to develop a biocompatible albumin-based nanoparticle carrier system for the controlled release of celastrol in diet-induced obese mice. Celastrol was loaded into bovine serum albumin (BSA) nanoparticles to yield celastrol-BSA-NPs by high pressure homogenization. Celastrol-BSA-NPs exhibited spherical morphology, narrow size distribution with a diameter of 125.6 ± 2.2 nm, satisfactory drug-loading efficiency at 13.88 ± 0.12% and a sustained-release profile over a period of 168 h. Compared with free celastrol, celastrol-BSA-NPs effectively improved cellular uptake, intestinal absorption and hepatic deposition. In animal experiments, celastrol-BSA-NPs outperformed free celastrol in lowering lipid accumulation, improving insulin sensitivity, and reducing inflammation in diet-induced obesity. Collectively, celastrol-BSA-NPs exhibited better bioavailability and in vivo efficacy in the treatment of diet-induced obesity. Importantly, such albumin-based nanoparticles may be a general biocompatible drug carrier system for the controlled release of hydrophobic compounds (e.g., celastrol) for the treatment of obesity and non-alcoholic fatty liver disease.-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats